Seventeen randomized, controlled, double-blind trials with 4,041 patients were included. Eligible trials included patients aged 40 years or older who were diagnosed with COPD with a postbronchodilator forced expiratory volume at 1 second/forced vital capacity of less than 0.7. The literature search was performed in the MEDLINE, Central, and Embase databases for articles published between January 1, 2012, and December 31, 2021. According to a recent publication in the journal, Respiratory Research, in patients with COPD, the use of long-acting muscarinic antagonist (LAMA) and long-acting beta-2 agonist (LABA) combinations are more effective than monotherapy or placebo for most exercise capacity and physical activity outcomes.ĭue to the significance of exercise capacity and physical activity on the quality of life (QoL) of patients with COPD, researchers conducted a systematic review and meta-analysis of double-blind, randomized, controlled trials to assess the effect of the combination of LAMA/LABA bronchodilators compared with placebo or LAMA or LABA monotherapy on the exercise capacity and physical activity outcomes. Research has established that persistent airflow limitation and dyspnea may diminish exercise capacity and physical activity in patients with COPD.
0 Comments
Leave a Reply. |